Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Clin Infect Dis ; 30(5): 757-61, 2000 May.
Artigo em Inglês | MEDLINE | ID: mdl-10816144

RESUMO

Acyclovir or similar agents with activity against Epstein-Barr virus (EBV) theoretically may prevent non-Hodgkin's lymphoma (NHL) in AIDS. A case-control study of 29 patients with AIDS-related NHL and 58 matched control subjects assessed the frequency with which daily acyclovir (>/=800 mg/d) or similar agents were used for > or =1 year. In a historical cohort of 304 patients with AIDS for > or =2 years, the prevalence of NHL was assessed among 3 groups of patients: those who received long-term treatment with high-dose acyclovir (or similar agents) or low-dose or intermittent acyclovir; those treated with ganciclovir/foscarnet for <1 year; and those who had not previously been treated with acyclovir, ganciclovir, or foscarnet. In the case-control study, 22 patients (72.4%) with NHL never received acyclovir or similar drugs versus 19 control subjects (32.8%; P=. 002); 2 patients (6.9%) with NHL received acyclovir (> or =800 mg/d) for > or =1 year versus 27 (46.6%) of control subjects (P=.0001). In the cohort study, 6 (6.8%) of 88 patients who received acyclovir (> or =800 mg/d) for > or =1 year developed NHL versus 15 (15.5%) of 97 patients who received intermittent or lower-dose acyclovir and 30 (25.2%) of 119 patients who never received these agents (P=.002). Long-term administration (>1 year) of high-dose acyclovir or similar agents with anti-EBV activity may prevent NHL in patients with AIDS. A prospective, randomized study is warranted to confirm these results.


Assuntos
Aciclovir/uso terapêutico , Antivirais/uso terapêutico , Linfoma Relacionado a AIDS/prevenção & controle , Adulto , Estudos de Casos e Controles , Estudos de Coortes , Quimioterapia Combinada , Infecções por Vírus Epstein-Barr/tratamento farmacológico , Feminino , Foscarnet/uso terapêutico , Ganciclovir/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Tempo
2.
J Otolaryngol ; 23(1): 46-9, 1994 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-8170020

RESUMO

Esthetic reconstruction of facial defects requires the use of skin with similar characteristics to that of the deficient site. Local and regional skin are the most suitable, but the amount available may be insufficient for both reconstruction and primary closure of the donor site. We describe three illustrative cases in which tissue expansion of local and regional skin allowed satisfactory reconstruction and donor site closure that would otherwise not have been possible.


Assuntos
Orelha Externa/cirurgia , Rinoplastia/métodos , Couro Cabeludo/cirurgia , Expansão de Tecido/métodos , Adulto , Idoso , Carcinoma Basocelular/cirurgia , Orelha Externa/lesões , Humanos , Masculino , Neoplasias Nasais/cirurgia , Úlcera Cutânea/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA